

## ITALY, 26 registries (1992-2013)

	Number of cases							Percentage				Incidence rates per million person-years							MV %	DCO %		
	Age group							0-14		0-19		Age-specific					Cumulative					
	0	1-4	5-9	10-14	15-19	0-14	0-19	All	Group	All	Group	0	1-4	5-9	10-14	15-19	0-14	0-19			0-14	0-19
<b>I LEUKAEMIA</b>	103	1012	686	503	499	2304	2803	30.7	100.0	24.0	100.0	37.5	92.4	50.7	36.3	33.1	58.4	52.7	841	1007	97.9	0.3
a. Lymphoid	48	883	571	343	252	1845	2097	24.5	80.1	18.0	74.8	17.5	80.6	42.2	24.7	16.7	47.1	40.2	674	758	98.6	0.1
b. Acute myeloid	30	85	85	115	136	315	451	4.2	13.7	3.9	16.1	10.9	7.8	6.3	8.3	9.0	7.7	8.0	115	160	98.0	0.4
c. CMD	9	13	14	33	75	69	144	0.9	3.0	1.2	5.1	3.3	1.2	1.0	2.4	5.0	1.6	2.4	25	50	99.3	0.0
d. MDS & other	7	13	4	4	9	28	37	0.4	1.2	0.3	1.3	2.5	1.2	0.3	0.3	0.6	0.7	0.7	10	13	97.3	0.0
e. Unspecified	9	18	12	8	27	47	74	0.6	2.0	0.6	2.6	3.3	1.6	0.9	0.6	1.8	1.2	1.3	17	26	74.3	6.8
<b>II LYMPHOMA &amp; RELATED</b>	28	151	315	629	1223	1123	2346	14.9	100.0	20.1	100.0	10.2	13.8	23.3	45.4	81.2	25.7	38.2	408	815	98.7	0.1
a. Hodgkin	0	20	84	371	888	475	1363	6.3	42.3	11.7	58.1	-	1.8	6.2	26.8	59.0	10.3	21.3	172	467	99.6	0.0
b. Non-Hodgkin except BL	6	46	111	157	272	320	592	4.3	28.5	5.1	25.2	2.2	4.2	8.2	11.3	18.1	7.4	9.8	117	207	99.5	0.2
c. Burkitt (BL)	1	39	87	69	28	196	224	2.6	17.5	1.9	9.5	0.4	3.6	6.4	5.0	1.9	4.6	4.0	72	81	100.0	0.0
d. Lymphoreticular	21	38	26	14	9	99	108	1.3	8.8	0.9	4.6	7.6	3.5	1.9	1.0	0.6	2.6	2.1	36	39	97.2	0.0
e. Unspecified	0	8	7	18	26	33	59	0.4	2.9	0.5	2.5	-	0.7	0.5	1.3	1.7	0.8	1.0	12	21	67.8	3.4
<b>III CNS NEOPLASMS †</b>	87	491	525	451	488	1554	2042	20.7	100.0	17.5	100.0	31.6	44.8	38.8	32.5	32.4	38.3	37.0	567	729	73.3	0.5
a. Ependymoma	15	68	40	33	29	156	185	2.1	10.0	1.6	9.1	5.5	6.2	3.0	2.4	1.9	4.0	3.5	57	67	97.3	0.0
b. Astrocytoma	23	165	193	149	135	530	665	7.1	34.1	5.7	32.6	8.4	15.1	14.3	10.7	9.0	13.0	12.1	194	238	97.1	0.0
c. CNS embryonal	15	92	103	55	47	265	312	3.5	17.1	2.7	15.3	5.5	8.4	7.6	4.0	3.1	6.6	5.8	97	113	99.0	0.0
d. Other gliomas	4	45	31	50	40	130	170	1.7	8.4	1.5	8.3	1.5	4.1	2.3	3.6	2.7	3.2	3.1	47	61	68.8	0.0
e. Other specified	7	33	39	56	90	135	225	1.8	8.7	1.9	11.0	2.5	3.0	2.9	4.0	6.0	3.2	3.8	49	79	83.6	0.0
f. Unspecified CNS	23	88	119	108	147	338	485	4.5	21.8	4.2	23.8	8.4	8.0	8.8	7.8	9.8	8.2	8.6	123	172	11.8	2.3
<b>IV NEUROBLASTOMA</b>	200	248	76	21	11	545	556	7.3	100.0	4.8	100.0	72.7	22.6	5.6	1.5	0.7	14.9	11.7	199	203	96.8	0.0
a. (Ganglio)neuroblastoma	198	242	70	13	4	523	527	7.0	96.0	4.5	94.8	72.0	22.1	5.2	0.9	0.3	14.4	11.2	191	192	96.8	0.0
b. Peripheral nervous	2	6	6	8	7	22	29	0.3	4.0	0.2	5.2	0.7	0.5	0.4	0.6	0.5	0.5	0.5	8	10	96.6	0.0
<b>V RETINOBLASTOMA</b>	75	78	2	1	1	156	157	2.1	100.0	1.3	100.0	27.3	7.1	0.1	0.1	0.1	4.4	3.4	57	57	73.2	0.0
<b>VI RENAL TUMOURS</b>	51	188	80	18	15	337	352	4.5	100.0	3.0	100.0	18.5	17.2	5.9	1.3	1.0	9.0	7.2	123	128	93.8	0.0
a. Nephroblastoma	48	180	67	8	1	303	304	4.0	89.9	2.6	86.4	17.5	16.4	4.9	0.6	0.1	8.2	6.4	111	111	98.0	0.0
b. Renal carcinoma	0	3	7	9	12	19	31	0.3	5.6	0.3	8.8	-	0.3	0.5	0.6	0.8	0.4	0.5	7	11	100.0	0.0
c. Unspecified	3	5	6	1	2	15	17	0.2	4.5	0.1	4.8	1.1	0.5	0.4	0.1	0.1	0.4	0.3	5	6	5.9	0.0
<b>VII HEPATIC TUMOURS</b>	29	36	9	8	13	82	95	1.1	100.0	0.8	100.0	10.5	3.3	0.7	0.6	0.9	2.2	1.9	30	34	90.5	1.1
a. Hepatoblastoma	25	29	6	3	1	63	64	0.8	76.8	0.5	67.4	9.1	2.6	0.4	0.2	0.1	1.7	1.4	23	23	100.0	0.0
b. Hepatic carcinoma	1	3	3	4	12	11	23	0.1	13.4	0.2	24.2	0.4	0.3	0.2	0.3	0.8	0.3	0.4	4	8	87.0	0.0
c. Unspecified	3	4	0	1	0	8	8	0.1	9.8	0.1	8.4	1.1	0.4	-	0.1	-	0.2	0.2	3	3	25.0	12.5
<b>VIII BONE TUMOURS</b>	4	25	94	230	215	353	568	4.7	100.0	4.9	100.0	1.5	2.3	6.9	16.6	14.3	7.9	9.3	128	200	94.4	0.2
a. Osteosarcoma	1	4	33	100	100	138	238	1.8	39.1	2.0	41.9	0.4	0.4	2.4	7.2	6.6	3.0	3.8	50	83	99.6	0.0
b. Chondrosarcoma	0	0	2	7	11	9	20	0.1	2.5	0.2	3.5	-	-	0.1	0.5	0.7	0.2	0.3	3	7	100.0	0.0
c. Ewing & related	1	18	48	99	78	166	244	2.2	47.0	2.1	43.0	0.4	1.6	3.5	7.1	5.2	3.8	4.1	60	86	98.4	0.0
d. Other specified	0	1	4	4	9	9	18	0.1	2.5	0.2	3.2	-	0.1	0.3	0.3	0.6	0.2	0.3	3	6	100.0	0.0
e. Unspecified	2	2	7	20	17	31	48	0.4	8.8	0.4	8.5	0.7	0.2	0.5	1.4	1.1	0.7	0.8	11	17	43.8	2.1
<b>IX SOFT TISSUE SARCOMA</b>	49	105	110	138	224	402	626	5.3	100.0	5.4	100.0	17.8	9.6	8.1	10.0	14.9	9.9	11.0	147	221	99.5	0.0
a. Rhabdomyosarcoma	19	69	56	51	57	195	252	2.6	48.5	2.2	40.3	6.9	6.3	4.1	3.7	3.8	4.9	4.6	71	90	100.0	0.0
b. Fibrosarcoma	10	5	11	17	22	43	65	0.6	10.7	0.6	10.4	3.6	0.5	0.8	1.2	1.5	1.0	1.1	16	23	100.0	0.0
c. Kaposi sarcoma	0	1	0	0	2	1	3	0.0	0.2	0.0	0.5	-	0.1	-	-	0.1	0.0	0.1	0	1	100.0	0.0
d. Other specified	13	20	29	51	124	113	237	1.5	28.1	2.0	37.9	4.7	1.8	2.1	3.7	8.2	2.7	3.9	41	82	99.2	0.0
e. Unspecified	7	10	14	19	19	50	69	0.7	12.4	0.6	11.0	2.5	0.9	1.0	1.4	1.3	1.2	1.2	18	25	98.6	0.0
<b>X GERM CELL TUMOURS</b>	33	46	28	90	422	197	619	2.6	100.0	5.3	100.0	12.0	4.2	2.1	6.5	28.0	4.8	10.0	72	212	97.1	0.0
a. CNS germ cell ‡	6	8	12	30	22	56	78	0.7	28.4	0.7	12.6	2.2	0.7	0.9	2.2	1.5	1.3	1.3	20	28	93.6	0.0
b. Other extragonadal	19	24	1	3	11	47	58	0.6	23.9	0.5	9.4	6.9	2.2	0.1	0.2	0.7	1.3	1.2	17	21	98.3	0.0
c. Gonadal germ cell	7	14	12	48	350	81	431	1.1	41.1	3.7	69.6	2.5	1.3	0.9	3.5	23.2	1.9	6.7	29	146	100.0	0.0
d. Gonadal carcinoma	0	0	0	2	22	2	24	0.0	1.0	0.2	3.9	-	-	-	0.1	1.5	0.0	0.4	1	8	100.0	0.0
e. Unspecified gonadal	1	0	3	7	17	11	28	0.1	5.6	0.2	4.5	0.4	-	0.2	0.5	1.1	0.2	0.4	4	10	57.1	0.0
<b>XI CARCINOMA &amp; MELANOMA</b>	7	16	65	240	949	328	1277	4.4	100.0	10.9	100.0	2.5	1.5	4.8	17.3	63.0	7.2	19.8	119	434	99.5	0.0
a. Adrenocortical	5	3	0	1	7	9	16	0.1	2.7	0.1	1.3	1.8	0.3	-	0.1	0.5	0.2	0.3	3	6	100.0	0.0
b. Thyroid	0	3	22	92	420	117	537	1.6	35.7	4.6	42.1	-	0.3	1.6	6.6	27.9	2.5	8.2	42	182	99.4	0.0
c. Nasopharyngeal	0	0	1	9	25	10	35	0.1	3.0	0.3	2.7	-	-	0.1	0.6	1.7	0.2	0.5	4	12	100.0	0.0
d. Melanoma	0	4	14	57	220	75	295	1.0	22.9	2.5	23.1	-	0.4	1.0	4.1	14.6	1.6	4.6	27	100	98.6	0.0
e. Skin carcinoma	1	4	16	32	114	53	167	0.7	16.2	1.4	13.1	0.4	0.4	1.2	2.3	7.6	1.2	2.6	19	57	100.0	0.0
f. Other & unspecified	1	2	12	49	163	64	227	0.9	19.5	1.9	17.8	0.4	0.2	0.9	3.5	10.8	1.4	3.5	23	77	100.0	0.0
<b>XII OTHER &amp; UNSPECIFIED</b>	33	39	25	39	86	136	222	1.8	100.0	1.9	100.0	12.0	3.6	1.8	2.8	5.7	3.4	4.0	50	78	29.3	1.8
a. Other specified	3	12	0	1	12	16	28	0.2	11.8	0.2	12.6	1.1	1.1	-	0.1	0.8	0.4	0.5	6	10	100.0	0.0
b. Other unspecified	30	27	25	38	74	120	194	1.6	88.2	1.7	87.4	10.9	2.5	1.8	2.7	4.9	3.0	3.4	44	68	19.1	2.1
<b>TOTAL §</b>	699	2435	2015	2368	4146	7517	11663	100.0	100.0	100.0	100.0	254.2	222.2	148.8	170.7	275.4	186.1	206.2	2741	4118	91.9	0.2

† includes 772 non-malignant ‡ includes 6 non-malignant

§ includes 1 with sex unknown

Please consult the quality indicators for the constituent registries

## ITALY, 26 registries (1992-2013)

	Males										M/F ratio		Females											
	Number of cases in age groups										0-14	0-19	Number of cases in age groups										0-14	0-19
	0	1-4	5-9	10-14	15-19	0-14	0-19	ASR per million	0-14	0-19			0	1-4	5-9	10-14	15-19	0-14	0-19	ASR per million	0-14	0-19		
<b>I LEUKAEMIA</b>	50	557	389	294	309	1290	1599	63.3	58.1	1.3	1.3	53	455	297	209	190	1014	1204	53.1	47.0				
a. Lymphoid	24	485	328	202	171	1039	1210	51.4	44.8	1.3	1.4	24	398	243	141	81	806	887	42.5	35.4				
b. Acute myeloid	14	47	46	63	77	170	247	8.0	8.5	1.2	1.2	16	38	39	52	59	145	204	7.3	7.5				
c. CMD	4	9	6	23	40	42	82	1.9	2.7	1.6	1.3	5	4	8	10	35	27	62	1.3	2.1				
d. MDS & other	2	6	3	2	5	13	18	0.7	0.7	0.9	0.9	5	7	1	2	4	15	19	0.8	0.8				
e. Unspecified	6	10	6	4	16	26	42	1.3	1.5	1.2	1.3	3	8	6	4	11	21	32	1.1	1.2				
<b>II LYMPHOMA &amp; RELATED</b>	16	100	231	364	661	711	1372	31.9	44.0	1.7	1.4	12	51	84	265	561	412	973	19.2	32.1				
a. Hodgkin	0	18	58	194	440	270	710	11.6	21.8	1.3	1.1	0	2	26	177	447	205	652	9.0	20.7				
b. Non-Hodgkin except BL	2	33	78	96	176	209	385	9.4	12.4	1.9	1.9	4	13	33	61	96	111	207	5.2	7.0				
c. Burkitt (BL)	0	26	75	52	21	153	174	7.0	6.1	3.6	3.5	1	13	12	17	7	43	50	2.1	1.9				
d. Lymphoreticular	14	19	16	10	6	59	65	3.0	2.5	1.5	1.5	7	19	10	4	3	40	43	2.2	1.8				
e. Unspecified	0	4	4	12	18	20	38	0.9	1.2	1.5	1.8	0	4	3	6	8	13	21	0.6	0.7				
<b>III CNS NEOPLASMS †</b>	47	260	289	228	239	824	1063	39.5	37.6	1.1	1.1	40	231	236	223	249	730	979	36.9	36.3				
a. Ependymoma	9	40	19	15	14	83	97	4.2	3.6	1.1	1.1	6	28	21	18	15	73	88	3.8	3.4				
b. Astrocytoma	10	90	106	62	71	268	339	12.9	12.1	1.0	1.0	13	75	87	87	64	262	326	13.1	12.1				
c. CNS embryonal	8	54	61	38	28	161	189	7.8	6.8	1.5	1.5	7	38	42	17	19	104	123	5.4	4.8				
d. Other gliomas	2	25	19	25	20	71	91	3.4	3.2	1.2	1.2	2	20	12	25	20	59	79	2.9	2.9				
e. Other specified	4	15	18	30	49	67	116	3.1	3.8	1.0	1.1	3	18	21	26	41	68	109	3.4	3.9				
f. Unspecified CNS	14	36	66	58	57	174	231	8.2	8.0	1.1	0.9	9	52	53	50	90	164	254	8.3	9.2				
<b>IV NEUROBLASTOMA</b>	104	139	42	12	4	297	301	15.8	12.3	1.2	1.2	96	109	34	9	7	248	255	14.0	11.0				
a. (Ganglioneuroblastoma	104	135	39	7	0	285	285	15.2	11.8	1.2	1.2	94	107	31	6	4	238	242	13.5	10.6				
b. Peripheral nervous	0	4	3	5	4	12	16	0.6	0.6	1.2	1.2	2	2	3	3	3	10	13	0.5	0.5				
<b>V RETINOBLASTOMA</b>	39	35	2	1	0	77	77	4.2	3.3	1.0	1.0	36	43	0	0	1	79	80	4.6	3.6				
<b>VI RENAL TUMOURS</b>	27	89	27	14	9	157	166	8.2	6.6	0.9	0.9	24	99	53	4	6	180	186	9.9	7.9				
a. Nephroblastoma	25	86	22	7	0	140	140	7.4	5.7	0.9	0.9	23	94	45	1	1	163	164	9.1	7.0				
b. Renal carcinoma	0	1	2	6	8	9	17	0.4	0.5	0.9	1.2	0	2	5	3	4	10	14	0.5	0.5				
c. Unspecified	2	2	3	1	1	8	9	0.4	0.3	1.1	1.1	1	3	3	0	1	7	8	0.4	0.3				
<b>VII HEPATIC TUMOURS</b>	19	21	7	7	7	54	61	2.8	2.4	1.9	1.8	10	15	2	1	6	28	34	1.6	1.4				
a. Hepatoblastoma	16	17	5	2	0	40	40	2.1	1.6	1.7	1.7	9	12	1	1	1	23	24	1.3	1.0				
b. Hepatic carcinoma	1	1	2	4	7	8	15	0.4	0.5	2.7	1.9	0	2	1	0	5	3	8	0.2	0.3				
c. Unspecified	2	3	0	1	0	6	6	0.3	0.2	3.0	3.0	1	1	0	0	0	2	2	0.1	0.1				
<b>VIII BONE TUMOURS</b>	2	14	46	128	141	190	331	8.2	10.5	1.2	1.4	2	11	48	102	74	163	237	7.5	8.1				
a. Osteosarcoma	0	1	20	54	68	75	143	3.2	4.4	1.2	1.5	1	3	13	46	32	63	95	2.9	3.2				
b. Chondrosarcoma	0	0	0	7	6	7	13	0.3	0.4	3.5	1.9	0	0	2	0	5	2	7	0.1	0.2				
c. Ewing & related	0	10	23	57	53	90	143	3.9	4.6	1.2	1.4	1	8	25	42	25	76	101	3.6	3.5				
d. Other specified	0	1	1	0	5	2	7	0.1	0.2	0.3	0.6	0	0	3	4	4	7	11	0.3	0.4				
e. Unspecified	2	2	2	10	9	16	25	0.7	0.8	1.1	1.1	0	0	5	10	8	15	23	0.7	0.8				
<b>IX SOFT TISSUE SARCOMA</b>	34	64	66	70	125	234	359	11.3	12.4	1.4	1.3	15	41	44	68	99	168	267	8.3	9.5				
a. Rhabdomyosarcoma	14	42	39	26	41	121	162	5.9	5.8	1.6	1.8	5	27	17	25	16	74	90	3.8	3.4				
b. Fibrosarcoma	7	2	4	8	10	21	31	1.0	1.1	1.0	0.9	3	3	7	9	12	22	34	1.1	1.2				
c. Kaposi sarcoma	0	1	0	0	2	1	3	0.1	0.1	-	-	0	0	0	0	0	0	0	-	-				
d. Other specified	7	12	13	25	62	57	119	2.7	3.9	1.0	1.0	6	8	16	26	62	56	118	2.7	4.0				
e. Unspecified	6	7	10	11	10	34	44	1.6	1.6	2.1	1.8	1	3	4	8	9	16	25	0.8	0.9				
<b>X GERM CELL TUMOURS</b>	20	21	9	38	334	88	422	4.2	13.0	0.8	2.1	13	25	19	52	88	109	197	5.4	6.9				
a. CNS germ cell ‡	4	6	7	18	17	35	52	1.6	1.7	1.7	2.0	2	2	5	12	5	21	26	1.0	0.9				
b. Other extragonadal	8	4	0	2	7	14	21	0.7	0.8	0.4	0.6	11	20	1	1	4	33	37	1.9	1.6				
c. Gonadal germ cell	7	11	1	14	292	33	325	1.6	9.7	0.7	3.1	0	3	11	34	58	48	106	2.2	3.5				
d. Gonadal carcinoma	0	0	0	0	6	0	6	-	0.2	0.0	0.3	0	0	0	2	16	2	18	0.1	0.6				
e. Unspecified gonadal	1	0	1	4	12	6	18	0.3	0.6	1.2	1.8	0	0	2	3	5	5	10	0.2	0.3				
<b>XI CARCINOMA &amp; MELANOMA</b>	1	6	26	100	334	133	467	5.7	14.1	0.7	0.6	6	10	39	140	615	195	810	8.9	25.8				
a. Adrenocortical	1	1	0	1	1	3	4	0.2	0.1	0.5	0.3	4	2	0	0	6	6	12	0.3	0.5				
b. Thyroid	0	2	8	36	103	46	149	1.9	4.5	0.6	0.4	0	1	14	56	317	71	388	3.2	12.2				
c. Nasopharyngeal	0	0	1	8	10	9	19	0.4	0.6	9.0	1.2	0	0	0	1	15	1	16	0.0	0.5				
d. Melanoma	0	1	3	24	100	28	128	1.2	3.8	0.6	0.8	0	3	11	33	120	47	167	2.1	5.3				
e. Skin carcinoma	0	2	8	8	47	18	65	0.8	2.0	0.5	0.6	1	2	8	24	67	35	102	1.6	3.3				
f. Other & unspecified	0	0	6	23	73	29	102	1.2	3.1	0.8	0.8	1	2	6	26	90	35	125	1.6	4.0				
<b>XII OTHER &amp; UNSPECIFIED</b>	19	24	13	15	38	71	109	3.6	3.9	1.1	1.0	14	15	12	24	48	65	113	3.3	4.0				
a. Other specified	2	8	0	0	5	10	15	0.5	0.6	1.7	1.2	1	4	0	1	7	6	13	0.3	0.5				
b. Other unspecified	17	16	13	15	33	61	94	3.0	3.3	1.0	0.9	13	11	12	23	41	59	100	3.0	3.6				
<b>TOTAL</b>	378	1330	1147	1271	2201	4126	6327	198.7	218.1	1.2	1.2	321	1105	868	1097	1944	3391	5335	172.7	193.6				

† includes 376 non-malignant in males and 396 non-malignant in females ‡ includes 4 non-malignant in males and 2 non-malignant in females

Please consult the quality indicators for the constituent registries

## ITALY, 26 registries (1992-2013)

	Age group	Males	Females
Person-years	0	1 413 907	1 335 690
	1-4	5 634 445	5 322 443
	5-9	6 960 781	6 581 229
	10-14	7 124 998	6 743 765
	15-19	7 731 970	7 322 105
Total	0-14	21 134 131	19 983 127
	0-19	28 866 101	27 305 232
Average annual population	0-14	960 642	908 324
	0-19	1 312 096	1 241 147

Please consult the quality indicators for the constituent registries

## ITALY, 26 registries (1992-2013)

Registry	Period	Cases	%	Person-years	%
Biella	1995-2010	137	1.2	588 324	1.0
Brescia	1999-2012	559	4.8	2 923 390	5.2
Catania	2003-2013	1044	9.0	4 530 969	8.1
Catanzaro	2003-2009	85	0.7	459 923	0.8
Como	2003-2011	229	2.0	952 520	1.7
Ferrara	1991-2011	227	1.9	974 075	1.7
Friuli-Venezia Giulia	1995-2010	620	5.3	3 040 691	5.4
Lecco	2003-2010	92	0.8	493 225	0.9
Lodi and Pavia	2003-2009	187	1.6	871 351	1.6
Milan	1999-2007	356	3.1	1 686 328	3.0
Modena	1990-2012	465	4.0	2 351 139	4.2
Naples	1996-2012	727	6.2	3 233 449	5.8
Nuoro	2003-2012	99	0.8	417 795	0.7
Parma	1992-2013	325	2.8	1 452 583	2.6
Ragusa	1992-2012	364	3.1	1 844 943	3.3
Reggio Emilia	1996-2012	313	2.7	1 514 558	2.7
Romagna	1990-2012	782	6.7	3 726 779	6.6
Salerno	1997-2009	698	6.0	3 265 591	5.8
Sassari	1992-2011	381	3.3	1 879 736	3.3
Syracuse	1999-2012	213	1.8	1 210 439	2.2
Trapani	2002-2009	137	1.2	743 243	1.3
Trento	2001-2010	172	1.5	996 225	1.8
Turin	1992-2012	540	4.6	2 970 190	5.3
Umbria	1994-2011	610	5.2	2 608 763	4.6
Varese	1992-2012	672	5.8	3 245 012	5.8
Veneto	1992-2009	1629	14.0	8 190 092	14.6
<b>ITALY</b>	<b>1992-2013</b>	<b>11663</b>	<b>100.0</b>	<b>56 171 333</b>	<b>100.0</b>

Please consult the quality indicators for the constituent registries

International Incidence of Childhood Cancer Volume III <http://iicc.iarc.fr/results>

## Europe

Como  
(2003-2011)Ferrara  
(1991-2011)Lodi and Pavia  
(2003-2009)

	Como (2003-2011)			Ferrara (1991-2011)			Lodi and Pavia (2003-2009)											
	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR						
<b>I LEUKAEMIA</b>	45	0.9	65.8	56	0.9	61.6	31	0.9	46.8	43	1.0	45.9	38	1.5	60.1	45	1.6	53.9
a. Lymphoid	38	0.9	56.0	45	0.9	50.2	21	1.1	32.2	27	1.3	29.8	33	1.8	52.1	36	1.8	43.5
b. Acute myeloid	6	0.5	8.5	9	0.8	9.5	6	0.5	8.6	7	0.8	7.4	2	.	3.2	5	4.0	5.6
c. CMD	1	.	1.2	2	1.0	1.9	1	0.0	1.2	5	0.3	4.2	1	0.0	1.5	2	1.0	2.2
d. MDS & other	0	.	.	0	.	.	1	.	1.4	1	.	1.1	0	.	.	0	.	.
e. Unspecified	0	.	.	0	.	.	2	1.0	3.4	3	2.0	3.4	2	0.0	3.4	2	0.0	2.6
<b>II LYMPHOMA &amp; RELATED</b>	17	2.4	22.4	46	1.3	45.3	27	2.9	36.2	47	2.4	44.2	20	1.9	29.5	41	2.2	44.8
a. Hodgkin	3	2.0	3.8	27	0.7	26.1	7	1.3	9.0	23	1.6	19.9	7	0.8	10.3	23	1.9	24.7
b. Non-Hodgkin except BL	8	3.0	10.5	13	5.5	12.9	14	3.7	18.1	17	3.3	16.5	5	1.5	7.3	9	1.3	9.8
c. Burkitt (BL)	6	2.0	8.1	6	2.0	6.3	4	3.0	5.9	5	4.0	5.4	5	.	7.2	6	.	6.6
d. Lymphoreticular	0	.	.	0	.	.	2	.	3.1	2	.	2.4	3	2.0	4.7	3	2.0	3.6
e. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
<b>III CNS NEOPLASMS †</b>	32	1.3	45.9	49	0.7	51.9	33	1.4	50.5	41	1.0	45.6	11	0.4	16.5	17	1.1	19.0
a. Ependymoma	6	1.0	9.2	7	0.8	8.1	2	.	3.4	4	3.0	4.2	1	0.0	1.5	2	1.0	2.2
b. Astrocytoma	8	1.7	11.5	11	0.8	11.8	12	3.0	18.2	14	1.8	15.7	3	0.5	4.5	6	2.0	6.6
c. CNS embryonal	5	1.5	7.2	7	1.3	7.5	6	1.0	8.8	7	0.8	7.6	1	0.0	1.5	1	0.0	1.2
d. Other gliomas	0	.	.	1	0.0	1.0	3	2.0	4.6	3	2.0	3.5	3	0.0	4.4	3	0.0	3.4
e. Other specified	8	0.6	10.8	12	0.5	12.2	3	0.5	5.0	4	0.3	4.7	0	.	.	0	.	.
f. Unspecified CNS	5	4.0	7.2	11	0.6	11.4	7	0.4	10.5	9	0.3	9.8	3	2.0	4.6	5	4.0	5.6
<b>IV NEUROBLASTOMA</b>	9	0.8	13.9	9	0.8	10.8	11	2.7	17.9	11	2.7	13.9	8	7.0	13.1	8	7.0	10.2
a. (Ganglio)neuroblastoma	9	0.8	13.9	9	0.8	10.8	11	2.7	17.9	11	2.7	13.9	8	7.0	13.1	8	7.0	10.2
b. Peripheral nervous	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
<b>V RETINOBLASTOMA</b>	4	0.3	6.3	4	0.3	4.9	2	0.0	3.4	2	0.0	2.6	1	.	1.7	1	.	1.3
<b>VI RENAL TUMOURS</b>	6	2.0	9.2	6	2.0	7.1	5	4.0	7.9	6	2.0	7.0	6	0.5	10.0	6	0.5	7.7
a. Nephroblastoma	6	2.0	9.2	6	2.0	7.1	5	4.0	7.9	5	4.0	6.1	6	0.5	10.0	6	0.5	7.7
b. Renal carcinoma	0	.	.	0	.	.	0	.	.	1	0.0	0.8	0	.	.	0	.	.
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
<b>VII HEPATIC TUMOURS</b>	2	1.0	3.1	2	1.0	2.4	0	.	.	0	.	.	1	.	1.7	1	.	1.3
a. Hepatoblastoma	2	1.0	3.1	2	1.0	2.4	0	.	.	0	.	.	1	.	1.7	1	.	1.3
b. Hepatic carcinoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
<b>VIII BONE TUMOURS</b>	10	0.7	13.1	13	0.9	13.0	7	6.0	9.4	12	5.0	11.3	6	1.0	8.4	9	0.5	9.6
a. Osteosarcoma	3	0.5	3.7	4	1.0	3.9	2	1.0	2.6	4	3.0	3.7	3	2.0	4.1	5	0.7	5.3
b. Chondrosarcoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
c. Ewing & related	4	1.0	5.4	6	1.0	6.1	3	.	3.7	5	4.0	4.5	3	0.5	4.2	3	0.5	3.3
d. Other specified	3	0.5	3.9	3	0.5	3.1	0	.	.	1	.	0.8	0	.	.	0	.	.
e. Unspecified	0	.	.	0	.	.	2	.	3.1	2	.	2.4	0	.	.	1	0.0	1.0
<b>IX SOFT TISSUE SARCOMA</b>	5	0.7	6.8	8	1.0	8.1	8	1.7	11.3	14	1.0	13.6	10	2.3	15.5	12	2.0	14.1
a. Rhabdomyosarcoma	4	1.0	5.5	5	1.5	5.2	3	.	4.8	4	.	4.5	8	1.7	12.4	9	2.0	10.7
b. Fibrosarcoma	1	0.0	1.2	1	0.0	1.0	0	.	.	0	.	.	1	.	1.7	1	.	1.3
c. Kaposi sarcoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
d. Other specified	0	.	.	2	1.0	1.9	4	1.0	5.3	9	0.5	8.1	1	.	1.4	2	1.0	2.1
e. Unspecified	0	.	.	0	.	.	1	0.0	1.2	1	0.0	1.0	0	.	.	0	.	.
<b>X GERM CELL TUMOURS</b>	3	2.0	4.2	16	2.2	15.8	3	.	5.0	11	.	10.4	3	0.5	4.8	9	3.5	10.0
a. CNS germ cell ‡	2	.	2.9	2	.	2.3	1	.	1.7	1	.	1.3	0	.	.	1	.	1.0
b. Other extragonadal	0	.	.	0	.	.	0	.	.	0	.	.	2	1.0	3.4	2	1.0	2.6
c. Gonadal germ cell	1	0.0	1.2	14	1.8	13.5	2	.	3.4	10	.	9.1	1	0.0	1.4	6	5.0	6.3
d. Gonadal carcinoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
e. Unspecified gonadal	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
<b>XI CARCINOMA &amp; MELANOMA</b>	4	1.0	5.2	19	0.7	18.5	7	0.2	8.8	31	0.8	26.2	7	1.3	10.1	22	0.4	23.5
a. Adrenocortical	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
b. Thyroid	1	.	1.2	8	0.3	7.7	7	0.2	8.8	20	0.4	17.3	1	0.0	1.4	6	0.0	6.3
c. Nasopharyngeal	0	.	.	1	.	1.0	0	.	.	2	1.0	1.6	0	.	.	0	.	.
d. Melanoma	0	.	.	5	0.7	4.8	0	.	.	2	1.0	1.6	5	4.0	7.3	8	1.7	8.8
e. Skin carcinoma	2	1.0	2.7	4	3.0	4.0	0	.	.	3	2.0	2.4	1	0.0	1.4	4	0.0	4.2
f. Other & unspecified	1	0.0	1.2	1	0.0	1.0	0	.	.	4	.	3.2	0	.	.	4	0.3	4.2
<b>XII OTHER &amp; UNSPECIFIED</b>	0	.	.	1	.	1.0	7	2.5	10.6	9	2.0	9.8	9	8.0	14.1	16	2.2	18.2
a. Other specified	0	.	.	1	.	1.0	0	.	.	0	.	.	0	.	.	0	.	.
b. Other unspecified	0	.	.	0	.	.	7	2.5	10.6	9	2.0	9.8	9	8.0	14.1	16	2.2	18.2
<b>TOTAL</b>	137	1.1	195.8	229	1.0	240.4	141	1.6	207.7	227	1.5	230.4	120	1.6	185.3	187	1.5	213.7

† includes 28 non-malignant in Como 17 non-malignant in Ferrara 2 non-malignant in Lodi and Pavia ‡ includes 1 non-malignant in Ferrara

Please consult the quality indicators for the constituent registries

Syracuse  
(1999-2012)Trento  
(2001-2010)

	0-14			0-19			0-14			0-19		
	Cases	M/F	ASR	Cases	M/F	ASR	Cases	M/F	ASR	Cases	M/F	ASR
<b>I LEUKAEMIA</b>	51	1.4	61.1	58	1.3	52.0	47	1.6	64.1	54	1.8	56.3
a. Lymphoid	36	1.6	44.4	40	1.5	37.0	38	1.9	51.8	41	1.9	43.0
b. Acute myeloid	12	1.4	13.0	13	1.6	10.7	2	1.0	2.7	3	2.0	3.0
c. CMD	0	.	.	1	0.0	0.7	4	0.3	5.5	7	1.3	7.1
d. MDS & other	1	0.0	1.4	1	0.0	1.1	0	.	.	0	.	.
e. Unspecified	2	1.0	2.4	3	0.5	2.5	3	2.0	4.0	3	2.0	3.1
<b>II LYMPHOMA &amp; RELATED</b>	17	1.1	19.7	42	0.9	31.7	9	2.0	11.0	26	1.4	24.6
a. Hodgkin	5	0.0	4.9	20	0.7	13.6	4	0.3	4.8	16	1.0	15.1
b. Non-Hodgkin except BL	7	1.3	8.6	15	0.9	11.9	1	.	1.2	4	0.3	3.7
c. Burkitt (BL)	3	.	3.7	4	3.0	3.5	3	.	3.8	5	.	4.8
d. Lymphoreticular	1	.	1.4	1	.	1.1	1	.	1.2	1	.	0.9
e. Unspecified	1	.	1.1	2	1.0	1.5	0	.	.	0	.	.
<b>III CNS NEOPLASMS</b> †	18	1.3	21.6	23	1.3	20.0	26	1.4	34.7	31	1.2	31.6
a. Ependymoma	2	1.0	2.9	3	0.5	2.9	3	0.5	4.2	4	1.0	4.2
b. Astrocytoma	7	0.4	7.8	9	0.8	7.4	12	2.0	15.8	13	1.6	13.2
c. CNS embryonal	3	2.0	3.2	5	1.5	3.8	3	2.0	3.9	4	1.0	4.0
d. Other gliomas	2	1.0	2.6	2	1.0	2.0	2	1.0	2.5	4	1.0	3.9
e. Other specified	0	.	.	0	.	.	0	.	.	0	.	.
f. Unspecified CNS	4	.	5.2	4	.	4.1	6	1.0	8.2	6	1.0	6.4
<b>IV NEUROBLASTOMA</b>	4	0.0	5.4	4	0.0	4.2	4	0.3	5.7	4	0.3	4.4
a. (Ganglio)neuroblastoma	4	0.0	5.4	4	0.0	4.2	4	0.3	5.7	4	0.3	4.4
b. Peripheral nervous	0	.	.	0	.	.	0	.	.	0	.	.
<b>V RETINOBLASTOMA</b>	4	3.0	5.7	4	3.0	4.4	3	.	4.5	3	.	3.5
<b>VI RENAL TUMOURS</b>	8	0.1	10.8	8	0.1	8.4	4	0.3	5.8	5	0.7	5.4
a. Nephroblastoma	8	0.1	10.8	8	0.1	8.4	4	0.3	5.8	4	0.3	4.5
b. Renal carcinoma	0	.	.	0	.	.	0	.	.	1	.	0.9
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.
<b>VII HEPATIC TUMOURS</b>	1	.	1.4	1	.	1.1	1	.	1.5	1	.	1.2
a. Hepatoblastoma	1	.	1.4	1	.	1.1	1	.	1.5	1	.	1.2
b. Hepatic carcinoma	0	.	.	0	.	.	0	.	.	0	.	.
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.
<b>VIII BONE TUMOURS</b>	8	1.0	7.7	11	1.8	7.9	5	.	6.0	6	.	5.6
a. Osteosarcoma	4	1.0	3.7	4	1.0	2.9	2	.	2.4	3	.	2.8
b. Chondrosarcoma	0	.	.	0	.	.	0	.	.	0	.	.
c. Ewing & related	3	2.0	3.0	6	5.0	4.3	1	.	1.2	1	.	0.9
d. Other specified	0	.	.	0	.	.	0	.	.	0	.	.
e. Unspecified	1	0.0	0.9	1	0.0	0.7	2	.	2.4	2	.	1.9
<b>IX SOFT TISSUE SARCOMA</b>	8	0.6	8.8	15	1.5	11.5	9	0.5	11.7	13	0.4	12.9
a. Rhabdomyosarcoma	4	1.0	4.7	4	1.0	3.7	1	0.0	1.3	2	0.0	1.9
b. Fibrosarcoma	0	.	.	0	.	.	0	.	.	0	.	.
c. Kaposi sarcoma	0	.	.	0	.	.	0	.	.	0	.	.
d. Other specified	2	0.0	2.1	8	1.7	5.5	5	0.7	6.4	5	0.7	5.0
e. Unspecified	2	1.0	2.1	3	2.0	2.3	3	0.5	4.0	6	0.5	6.0
<b>X GERM CELL TUMOURS</b>	4	0.3	4.6	16	1.3	11.5	2	0.0	2.4	6	1.0	5.6
a. CNS germ cell	1	0.0	0.9	1	0.0	0.7	0	.	.	0	.	.
b. Other extragonadal	1	0.0	1.4	1	0.0	1.1	0	.	.	0	.	.
c. Gonadal germ cell	1	0.0	1.1	12	2.0	8.1	1	0.0	1.2	5	1.5	4.7
d. Gonadal carcinoma	0	.	.	1	0.0	0.7	0	.	.	0	.	.
e. Unspecified gonadal	1	.	1.1	1	.	0.9	1	0.0	1.2	1	0.0	0.9
<b>XI CARCINOMA &amp; MELANOMA</b>	6	0.5	6.6	27	0.5	18.9	4	0.3	4.8	18	0.6	17.0
a. Adrenocortical	0	.	.	0	.	.	0	.	.	0	.	.
b. Thyroid	3	2.0	3.4	11	0.4	7.9	2	0.0	2.4	3	0.0	2.8
c. Nasopharyngeal	0	.	.	2	1.0	1.3	0	.	.	0	.	.
d. Melanoma	3	0.0	3.2	12	0.5	8.4	2	1.0	2.4	11	0.8	10.4
e. Skin carcinoma	0	.	.	0	.	.	0	.	.	2	.	1.9
f. Other & unspecified	0	.	.	2	1.0	1.3	0	.	.	2	0.0	1.9
<b>XII OTHER &amp; UNSPECIFIED</b>	0	.	.	4	.	2.6	4	0.3	5.8	5	0.3	5.4
a. Other specified	0	.	.	0	.	.	0	.	.	1	0.0	0.9
b. Other unspecified	0	.	.	4	.	2.6	4	0.3	5.8	4	0.3	4.5
<b>TOTAL</b>	129	1.0	153.5	213	1.0	174.3	118	1.3	157.8	172	1.2	173.4

† includes 5 non-malignant in Trento

Please consult the quality indicators for the constituent registries